Researchers were able to dissect the immune response leading to successful recovery from COVID-19, which might be the secret to finding an effective vaccine. Image: Doherty Institute
Melbourne researchers have mapped immune responses from one of Australia’s first novel coronavirus (COVID-19) patients, showing the body’s ability to fight the virus and recover from the infection.
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) – a joint venture between the University of Melbourne and the Royal Melbourne hospital – were able to test blood samples at four different time points in an otherwise healthy woman in her 40s, who presented with COVID-19 and had mild-to-moderate symptoms requiring hospital admission.
Published today in Nature Medicine is a detailed report of how the patient’s immune system responded to the virus. One of the authors on the paper, research fellow Dr Oanh Nguyen said this was the first time that broad immune responses to COVID-19 have been reported.
“We looked at the whole breadth of the immune response in this patient using the knowledge we have built over many years of looking at immune responses in patients hospitalised with influenza,” Dr Nguyen said.
“Three days after the patient was admitted, we saw large populations of several immune cells, which are often a tell-tale sign of recovery during seasonal influenza infection, so we predicted that the patient would recover in three days, which is what happened.”
The research team was able to do this research so rapidly thanks to SETREP-ID (Sentinel Travellers and Research Preparedness for Emerging Infectious Disease), led by Royal Melbourne Hospital Infectious Diseases Physician Dr Irani Thevarajan at the Doherty Institute.
SETREP-ID is a platform that enables a broad range of biological sampling to take place in returned travellers in the event of a new and unexpected infectious disease outbreak, which is exactly how COVID-19 started in Australia.
“When COVID-19 emerged, we already had ethics and protocols in place so we could rapidly start looking at the virus and immune system in great detail,” Dr Thevarajan said.
“Already established at a number of Melbourne hospitals, we now plan to roll out SETREP-ID as a national study.”
Working together with University of Melbourne Professor Katherine Kedzierska, a laboratory head at the Doherty Institute and a world-leading influenza immunology researcher, the team were able to dissect the immune response leading to successful recovery from COVID-19, which might be the secret to finding an effective vaccine.
“We showed that even though COVID-19 is caused by a new virus, in an otherwise healthy person, a robust immune response across different cell types was associated with clinical recovery, similar to what we see in influenza,” Professor Kedzierska said.
“This is an incredible step forward in understanding what drives recovery of COVID-19. People can use our methods to understand the immune responses in larger COVID-19 cohorts, and also understand what’s lacking in those who have fatal outcomes.”
Dr Thevarajan said that current estimates show more than 80 per cent of COVID-19 cases are mild-to-moderate, and understanding the immune response in these mild cases is very important research.
“We hope to now expand our work nationally and internationally to understand why some people die from COVID-19, and build further knowledge to assist in the rapid response of COVID-19 and future emerging viruses,” she said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Biden Administration: 5 Million Kids Under 12 Vaccinated Against COVID-19
Roughly 5 million children ages 5-11 will be at least partially vaccinated against the coronavirus by the end of day Tuesday, according to the Biden administration. White House COVID-19 response ...
- 'It's time to double down': Delaware reports nearly 50% increase in COVID-19 cases
The COVID-19 delta variant has led to a massive spike in cases with the state seeing about a 50% surge in cases in the last week.
- Louisiana Supreme Court hears arguments on Ochsner’s COVID-19 vaccine mandate
The Supreme Court of Louisiana heard arguments Tuesday about Ochsner's COVID-19 vaccine mandate for employees in, Shreveport and Monroe.
- Fact check: No, drinking water isn't testing positive for COVID-19 in rapid tests
There is no narration on the video, but some users on social media have been posting that it shows that tap water is testing positive for COVID-19. In a tweet on Dec. 5, a Canadian doctor wrote, "Tap ...
- Browns Activate LS Charley Hughlett, FB Johnny Stanton From Covid-19 List, Make Multiple Roster Moves
The Cleveland Browns made a flurry of roster moves on Tuesday that all revolved around COVID-19. The team placed TE David Njoku on the COVID-19 list, activated LS Charley Hughlett and FB Johnny ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Covid-19 immune system response
- No, taking activated charcoal won't affect COVID-19 vaccines
Doctors say since activated charcoal is ingested orally and does not enter a person’s bloodstream, it won’t affect the COVID-19 vaccines.
- Nose cells could be key target in fight against severe COVID-19
Scientists have shed new light on early events in the battle between COVID-19 and the immune system in the nose, a key entry point for the virus.
- Revealed: How SARS-CoV-2 evades our immune system
Scientists at Hokkaido University and Texas A&M University have identified a key mechanism used by the SARS-CoV-2 virus to evade host immune systems.
- New study investigates immune response and vaccine hesitancy among First Nations communities
The study, called COVID CommUNITY- First Nations, will collect, analyze, and report data relating to COVID-19 vaccine effectiveness and safety, as well as explore hesitancy in three First Nations ...
- Mixing Pfizer, AstraZeneca Covid-19 shots with Moderna gives better immune response, UK study suggests
A major British study into mixing Covid-19 vaccines found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine ...